Onesource Specialty Pharma
Market cap ₹18,190 Cr
- P/E
- 19.37
- Day range
- ₹1,563.40 – ₹1,592.40
- 52-week range
- ₹1,057.00 – ₹1,917.80
- Volume
- 1.59 L
- Open
- ₹1,580.80
- Prev close
- ₹1,580.80
Latest results · Q2 FY27(consolidated)Revenue ₹965 Cr+156.9%Profit ₹82 Cr+686.7%Margin 8.5%YoY vs the same quarter last year
1 red flag to read up on
- high
Promoter pledge went up
38.79% of promoter shares pledged, up from 37.23% · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
ONESOURCE in NSE indices and F&O
Research profile
Composite 47 / 100Factor percentiles
Derived metrics
- Earn. yield
- 5.2%
- Graham no.
- ₹106.72
- vs Graham
- -93.3%
- ROE ÷ P/B
- -0.4%
- 12-1 mom.
- -21.4%
- Return / vol
- -0.27
- Magic Formula
- #442
- Piotroski
- 5/6
- FCF yield
- -3.1%
- PEG
- 0.03
Appears in 10 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Onesource Specialty PharmaONESOURCE | ₹18,190 Cr | 19.37 | 3.13 | -1.3% | 1.0% | 32.0% | 0.30 | +37.2% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 3h agoHeadlines about Onesource Specialty Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 1617.0
- Price / Book
- 3.07
- ROE (FY26)
- -1.3%
- ROCE (latest year)
- 1%
- Dividend yield
- 0.00%
Moving averages (NSE)
- 20-day
- ₹1,543.4
- Price above
- 50-day
- ₹1,536.1
- Price above
- 200-day
- ₹1,548.82
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56 | 73 | 292 | 334 | 393 | 426 | 327 | 376 | 290 | 428 | 449 | 516 |
| YoY Sales growth | — | — | — | — | — | — | — | — | -26 | — | — | — |
| Expenses | 67 | 76 | 228 | 257 | 251 | 243 | 239 | 269 | 273 | 336 | 326 | 353 |
| Operating Profit | -10 | -3 | 64 | 77 | 142 | 183 | 88 | 106 | 17 | 92 | 123 | 163 |
| OPM % | -19% | -3.8% | 22% | 23% | 36% | 43% | 27% | 28% | 6% | 21% | 27% | 32% |
| Other Income | -74 | 3 | -1 | -1 | -94 | 2 | 2 | 3 | -2 | 2 | 0 | -1 |
| Interest | 26 | 20 | 42 | 45 | 46 | 33 | 27 | 34 | 38 | 23 | 31 | 35 |
| Depreciation | 20 | 20 | 68 | 68 | 69 | 68 | 68 | 70 | 70 | 72 | 72 | 75 |
| Profit before tax | -130 | -40 | -47 | -37 | -67 | 83 | -4 | 6 | -93 | 0 | 20 | 53 |
| Tax % | 0% | 0% | -88% | 12% | 4% | -19% | -96% | -83% | -5% | -1630% | -23% | -9% |
| Net Profit | -130 | -40 | -6 | -42 | -69 | 98 | 0 | 10 | -89 | 5 | 25 | 57 |
| EPS in Rs | — | — | — | — | ₹-6.02 | ₹8.61 | ₹-0.02 | ₹0.92 | ₹-7.74 | ₹0.40 | ₹2.18 | ₹5.01 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+139 days since Mar 2021
+351 days since Mar 2021
-455 days since Mar 2021
+945 days since Mar 2021
+2386 days since Mar 2021
Strengths, risks & growth
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics [1]
Strengths
None flagged by the checklist.
Risks
- Stock is trading at 3.12 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.63% over last 3 years.
- Promoters have pledged 38.8% of their holding.
- Company has high debtors of 177 days.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +131%
- 3 Years
- +232%
- TTM
- +11%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +8%
- 3 Years
- +24%
- TTM
- -92%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- 1 Year
- -10%
Return on Equity
- 10 Years
- —
- 5 Years
- -10%
- 3 Years
- -3%
- Last Year
- -1%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 29.93% | 30.48% | 30.48% | 30.47% | -0.01 pp |
| FII | 19.24% | 17.50% | 19.19% | 19.45% | +0.26 pp |
| DII | 18.80% | 20.61% | 23.37% | 24.20% | +0.83 pp |
| Public | 32.01% | 31.40% | 26.95% | 25.86% | -1.09 pp |
Filed with NSE for Sept 2026: promoters 30.47%, public 69.53%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 13.76% (+0.78 pp)- Promoters30.5%
- Foreign institutions19.5%
- Mutual funds13.8%
- Insurance4.1%
- Other domestic institutions6.3%
- Retail9.9%
- Others15.9%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Motilal Oswal Large & Midcap Fund | 3.31% | 3.04% | -0.32 pp |
| Motilal Oswal Flexi Cap Fund | 2.13% | 2.92% | +0.14 pp |
| Motilal Oswal ELSS Tax Saver Fund | 0.94% | 3.65% | -0.04 pp |
| 360 ONE Focused Fund | 0.91% | 2.55% | -0.01 pp |
| Axis Small Cap Fund | 0.79% | 0.49% | -0.00 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- Avg
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 42.9%
- Downside volatility
- 42.9%
- Worst 5% of days
- 3.7%
- Average of that tail
- 5.8%
- Max drawdown (1Y)
- 41.1%
- Below its peak
- 16.1%
Against the market
- Beta vs Nifty 50
- -0.08
- Correlation
- -0.03
- Relative strength (3M)
- -2.1%
- ATR (14)
- 3.7%
Return
- Return 1M
- +12.7%
- Return 3M
- +1.8%
- Return 6M
- -12.4%
- Return 1Y
- -11.5%
- vs 200-day average
- +2.4%
Momentum
- RSI (14)
- 55.5
- MACD histogram
- 4.24
- Stochastic %K
- 33.2
- ADX (14)
- 29.1
- +DI / −DI
- 25.1 / 15.8
- Money flow index
- 38.7
Participation
- Delivery (20d avg)
- 49.8%
- vs its 60-day baseline
- -0.8 pts
- Volume vs 20-day
- -0.4σ
- Close vs day's VWAP
- +0.2%
- 52-week position
- 61 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- -₹561 Cr
- FCF yield
- -3.1%
- Cash conversion
- -0.12
- Accruals ratio
- -0.010
- Net debt
- ₹1,741 Cr
- Net debt / equity
- 0.29
- EV / sales
- 9.34
- PEG
- 0.03
- Capex intensity
- 40.0%
- Revenue CAGR
- 72.4%
- Profit CAGR
- -11.0%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
TENSHI PHARMACEUTICALS PRIVATE LIMITED Promoters · Market Purchase | Buy | 85,000 | ₹1.0 Cr | 6 Feb 2026 |
TENSHI PHARMACEUTICALS PRIVATE LIMITED Promoters · Market Purchase | Buy | 2,05,000 | ₹23.9 Cr | 6 Feb 2026 |
PRONOMZ VENTURES LLP Promoter Group · Market Purchase | Buy | 33,906 | ₹4.0 Cr | 6 Feb 2026 |
Tenshi Pharmaceuticals Private Limited Promoters · Market Purchase | Buy | 75,000 | ₹8.7 Cr | 6 Feb 2026 |
PRONOMZ VENTURES LLP Promoter Group · Market Purchase | Buy | 45,000 | ₹5.1 Cr | 6 Feb 2026 |
Tenshi Pharmaceuticals Private Limited Promoters · Market Purchase | Buy | 2,00,000 | ₹2.1 Cr | 6 Feb 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
Company announcements
Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter ended September 30, 2026
Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve OneSource Specialty ....
Allotment of 900 Equity shares of Re. 1 each under ONESOURCE ESOP 2021 on September 25, 2026
Closure of trading window for the quarter ended September 30, 2026
Voting results along with Scrtuinizer's report for the 19th AGM
Intimation of appointment of M/s BSR and Co. LLP as the Statutory Auditors of the Company for a term of 5 consecutive years.
Proceedings of the 19th AGM (2nd AGM Post Listing) of the Company
Addendum to the notice of the 19th AGM scheduled to be held on September 23, 2026
Intimation of the investor presentation
Newspaper advertisement confirming the dispatch of the notice convening the 19th AGM of the Company and Remote e-voting
Intimation of the Notice of the 19th AGM (2nd AGM after listing), to be held on September 23, 2026 at 5:00 pm through Video Conferencing or other Audio Visual Means
Business Responsibility and Sustainability Report for the FY 2026
Annual Report for FY 2025-26
Annual Report for FY 2025-26
Intimation of Investors called scheduled on September 03, 2026 at 10:00 AM.
Filed with BSE (scrip 544292); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptRecording
- Jul 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Jan 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Sep 2025Slides
Credit ratings
- Rating update · 17 Aug from fitch
- Rating update · 5 Mar from care
- Rating update · 3 Jun 2025 from fitch
- Rating update · 20 Feb 2025 from care
- Rating update · 23 Sep 2024 from care
- Rating update · 25 Jul 2024 from care
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 27 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Onesource Specialty Pharma: common questions
Answered from the figures on this page.